$1.4B Mars Spend Puts Independent Pet Retail in the Squeeze

$1.4 billion.

That's what Mars will spend on U.S. manufacturing and operations in 2027, the largest single-year capital deployment in the company's 115-year history. The number alone is the story, but what Mars is buying with it is the part that changes the game for independent pet retailers.

The breakdown: owned hospitals, expanded capacity, and vertical control

Mars announced the investment will fund manufacturing expansion, new veterinary hospitals, and facility modernization across its U.S. footprint. The company operates more than 60 factories and over 2,000 veterinary clinics and hospitals in the U.S. and the $1.4 billion builds on more than $9 billion invested domestically since 2017.

Early next year, Mars will open four new veterinary hospitals, three BluePearl locations in Ellicott City, MD, Austin, TX, and Katy, TX, plus one Banfield hospital in Wilmington, NC, with a combined investment of more than $34 million. The facilities will add up to 195 jobs and expand Mars's owned veterinary footprint into growing markets.

The rest of the capital goes into manufacturing capacity and modernization. Mars said 94% of the products it sells in the U.S. are made domestically, and the investment is designed to scale production across its snacking and pet care portfolio, which now includes the Kellanova brands (Cheez-It, Pringles) acquired in the last year. The company added 15 new facilities through that deal and said it will continue modernizing the full portfolio.

What the $1.4B figure is NOT

This is not a bet on wholesale distribution. Mars is not announcing new partnerships with independent retailers, expanded broker networks, or better terms for specialty buyers. The capital is going into assets Mars owns and operates: factories it controls, hospitals it runs, and supply chains it doesn't share.

The investment also is not a one-time spike. Mars has deployed more than $9 billion into U.S. operations since 2017, and the $1.4 billion is the largest single year in that run. The pattern says Mars believes the future margin sits in vertical integration, owning more of the chain from ingredient to end customer, not in expanding the wholesale channel that independents rely on.

We write one of these every week for people who stock the brands this affects. subscribe to PetRetailNews.

The squeeze independents are already feeling

If you stock Royal Canin, Nutro, Greenies, Sheba, Pedigree, or Cesar, you are buying from a supplier that now operates more than 2,000 veterinary clinics in the U.S. and is opening more. Every new Banfield or BluePearl location is a retail point Mars controls, where it can recommend its own brands without splitting margin with you, and where the customer relationship belongs to Mars, not to the store that carried the SKU for years.

The vet hospital expansion is small in dollar terms, $34 million is a rounding error inside a $1.4 billion total, but it is directionally clear. Mars is building owned touchpoints with pet owners, and those touchpoints compete with independent retail for the same customer. A BluePearl vet recommending Royal Canin keeps the transaction inside Mars's ecosystem, and Mars gets paid whether the customer buys at the clinic, online, or walks into your store.

The manufacturing expansion compounds the problem. More capacity means Mars can afford to favor owned channels or demand better terms from distributors, because it has the volume to make wholesale a smaller percentage of total sales. Independents lose negotiating leverage on reorders when the supplier has more places to send the volume.

Mars is spending $1.4 billion to own more of the chain. Independents are price-takers on Mars SKUs and have no leverage to stop it.

Our read: the capital is the strategy, and the strategy doesn't include you

Mars CFO Claus Aagaard said the investment builds for the future, expanding manufacturing capabilities and ensuring the company can meet evolving consumer needs for generations to come. What he did not say: that future includes stronger partnerships with independent specialty retail.

The $1.4 billion is a bet that the best return comes from owning the customer relationship, the production line, and the distribution channel. For Mars, that makes sense. For independents carrying Mars brands, it means you are stocking products made by a competitor that is better capitalized, more vertically integrated, and less reliant on your shelf space than it was five years ago.

The risk is not that Mars pulls out of wholesale tomorrow. The risk is that expanded capacity and owned touchpoints give Mars options independents can't match. When a supplier has more leverage, terms get tighter and innovation flows to the channels the supplier controls.

What changes Monday

If Mars brands represent a meaningful portion of your dry food, treat, or wet food sets, you are exposed. The play is not to drop Royal Canin or Greenies, customers ask for them, and you lose the sale if you don't stock them. The play is to recognize that your supplier is building around you, and to build your own leverage in response.

That means:

Diversify your premium sets now, while you still have margin to test. If Royal Canin is your only vet-formulated dry food and Mars tightens terms or shifts volume to owned channels, you have no fallback. Stock a second therapeutic brand, a second premium treat line, a second topper that isn't owned by a vertically integrated competitor. Give yourself room to move if Mars makes wholesale less attractive.

Track turn rate on Mars SKUs separately. If you see volume start to slip on a Mars brand that has been steady for years, it may be early signal that Mars is shifting volume to owned channels or that customers are buying direct. Catch it early and you can reallocate the space before margin bleeds.

Do not build an endcap around a brand Mars owns unless the terms cover the risk. An endcap is a bet that the supplier wants your volume as much as you want theirs. Mars has 2,000+ owned vet clinics and $1.4 billion to build more. If the terms don't account for that, the endcap is a bad trade.

The $1.4 billion is the largest capital deployment Mars has ever made in a single year, and it is going into assets that compete with independent retail or reduce Mars's reliance on it. If you stock Mars brands, you are watching your supplier invest in a future where you have less leverage, not more. The time to build your own is before the terms change.

← Back to the Newsdesk